Search

Your search keyword '"Temperli, Fabrice"' showing total 16 results
Start Over Author "Temperli, Fabrice" Publication Year Range Last 10 years
16 results on '"Temperli, Fabrice"'

4. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.

Author

Ueki, Yasushi, Häner, Jonas D., Losdat, Sylvain, Gargiulo, Giuseppe, Shibutani, Hiroki, Bär, Sarah, Otsuka, Tatsuhiko, Kavaliauskaite, Raminta, Mitter, Vera R., Temperli, Fabrice, Spirk, David, Stortecky, Stefan, Siontis, George C. M., Valgimigli, Marco, Windecker, Stephan, Gutmann, Clemens, Koskinas, Konstantinos C., Mayr, Manuel, and Räber, Lorenz

Published
2024
Full Text
View/download PDF

5. Computed Tomography Scan Evidence for Left Atrial Appendage Short‐Term Remodeling Following Percutaneous Occlusion: Impact of Device Oversizing

Author

Mahmoudi, Khalil, primary, Galea, Roberto, additional, Elhadad, Simon, additional, Temperli, Fabrice, additional, Sebag, Frederic, additional, Gräni, Christoph, additional, Rezine, Zhor, additional, Roten, Laurent, additional, Landolff, Quentin, additional, Brugger, Nicolas, additional, Masri, Alaa, additional, Räber, Lorenz, additional, and Amabile, Nicolas, additional

Published
2023
Full Text
View/download PDF

6. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial

Author

Bär, Sarah, primary, Kavaliauskaite, Raminta, additional, Otsuka, Tatsuhiko, additional, Ueki, Yasushi, additional, Häner, Jonas D., additional, Siontis, George C.M., additional, Stortecky, Stefan, additional, Shibutani, Hiroki, additional, Temperli, Fabrice, additional, Kaiser, Christoph, additional, Iglesias, Juan F., additional, Jan van Geuns, Robert, additional, Daemen, Joost, additional, Spirk, David, additional, Engstrøm, Thomas, additional, Lang, Irene, additional, Windecker, Stephan, additional, Koskinas, Konstantinos C., additional, Losdat, Sylvain, additional, and Räber, Lorenz, additional

Published
2023
Full Text
View/download PDF

7. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial

Author

Bär, Sarah, Kavaliauskaite, Raminta, Otsuka, Tatsuhiko, Ueki, Yasushi, Häner, Jonas D, Siontis, George C M, Stortecky, Stefan, Shibutani, Hiroki, Temperli, Fabrice, Kaiser, Christoph, Iglesias, Juan, Jan van Geuns, Robert, Daemen, Joost, Spirk, David, Engstrøm, Thomas, Lang, Irene, Windecker, Stephan, Koskinas, Konstantinos C, Losdat, Sylvain, and Räber, Lorenz

Subjects
610 Medicine & health
Abstract

BACKGROUND Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on top of statins leads to plaque regression and stabilisation. The effects of PCSK9 inhibitors on coronary physiology and angiographic diameter stenosis (DS%) are unknown. AIMS This study aimed to investigate the effects of the PCSK9 inhibitor alirocumab on coronary haemodynamics as assessed by quantitative flow ratio (QFR) and DS% by three-dimensional quantitative coronary angiography (3D-QCA) in non-infarct-related arteries (non-IRA) among acute myocardial infarction (AMI) patients. METHODS This was a prespecified substudy of the randomised controlled PACMAN-AMI trial, comparing alirocumab versus placebo on top of rosuvastatin. QFR and 3D-QCA were assessed at baseline and 1 year in any non-IRA ≥2.0 mm and 3D-QCA DS% >25%. The prespecified primary endpoint was the number of patients with a mean QFR increase at 1 year, and the secondary endpoint was the change in 3D-QCA DS%. RESULTS Of 300 enrolled patients, 265 had serial follow-up, of which 193 underwent serial QFR/3D-QCA analysis in 282 non-IRA. At 1 year, QFR increased in 50/94 (53.2%) patients with alirocumab versus 40/99 (40.4%) with placebo (Δ12.8%; odds ratio 1.7, 95% confidence interval [CI]: 0.9 to 3.0; p=0.076). DS% decreased by 1.03±7.28% with alirocumab and increased by 1.70±8.27% with placebo (Δ-2.50%, 95% CI: -4.43 to -0.57; p=0.011). CONCLUSIONS Treatment of AMI patients with alirocumab versus placebo for 1 year resulted in a significant regression in angiographic DS%, whereas no overall improvement of coronary haemodynamics was observed. CLINICALTRIALS gov: NCT03067844.

Published
2023
Full Text
View/download PDF

8. Clinical outcomes in STEMI patients undergoing percutaneous coronary interventions later than 48 hours after symptom onset

Author

Rohla, Miklos, Temperli, Fabrice, Siontis, George C M, Klingenberg, Roland, Gencer, Baris, Rodondi, Nicolas, Bär, Sarah, Nanchen, David, Mach, Francois, Häner, Jonas D, Pilgrim, Thomas, Muller, Olivier, Matter, Christian M, Lüscher, Thomas, Roffi, Marco, Heg, Dierik, Windecker, Stephan, and Räber, Lorenz

Subjects
610 Medicine & health, 360 Social problems & social services
Abstract

BACKGROUND Routine revascularisation in patients with ST-segment-elevation myocardial infarction (STEMI) presenting >48 hours after symptom onset is not recommended. METHODS We compared outcomes of STEMI patients undergoing percutaneous coronary intervention (PCI) according to total ischemic time. Patients included in the Bern-PCI registry and the Multicenter Special Program University Medicine ACS (SPUM-ACS) between 2009-2019 were analysed. Based on symptom-to-balloon-time, patients were categorised as early (48 h). Co-primary endpoints were all-cause mortality and target lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction and target-lesion revascularisation at one year. RESULTS Of 6,589 STEMI patients undergoing PCI, 73.9% were early, 17.2% late and 8.9% very late presenters. Mean age was 63.4 years, 22% were female. At one year, all-cause mortality occurred more frequently in late vs. early (5.8% vs. 4.4%, HR 1.34,95%CI 1.01-1.78, p = 0.04) and very late (6.8%) vs. early presenters (HR 1.59, 95%CI 1.12-2.25, p 12 h after symptom onset was associated with less favourable outcomes, but very late vs. late presenters did not have an excess in events. While benefits seem uncertain, (very) late PCI appeared safe.

Published
2023
Full Text
View/download PDF

9. Clinical outcomes in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary interventions later than 48 h after symptom onset

Author

Rohla, Miklos, primary, Temperli, Fabrice, additional, Siontis, George C M, additional, Klingenberg, Roland, additional, Gencer, Baris, additional, Rodondi, Nicolas, additional, Bär, Sarah, additional, Nanchen, David, additional, Mach, Francois, additional, Häner, Jonas D, additional, Pilgrim, Thomas, additional, Muller, Olivier, additional, Matter, Christian M, additional, Lüscher, Thomas, additional, Roffi, Marco, additional, Heg, Dik, additional, Windecker, Stephan, additional, and Räber, Lorenz, additional

Published
2023
Full Text
View/download PDF

10. Acute Coronary Occlusion in Patients With Non-ST-Segment Elevation Out-of-Hospital Cardiac Arrest

Author

Spirito, Alessandro, primary, Vaisnora, Lukas, additional, Papadis, Athanasios, additional, Iacovelli, Fortunato, additional, Sardu, Celestino, additional, Selberg, Alexandra, additional, Bär, Sarah, additional, Kavaliauskaite, Raminta, additional, Temperli, Fabrice, additional, Asatryan, Babken, additional, Pilgrim, Thomas, additional, Hunziker, Lukas, additional, Heg, Dik, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, and Räber, Lorenz, additional

Published
2023
Full Text
View/download PDF

11. TCT-8 Frequency, Predictors, and Impact of Acute Coronary Occlusion in Patients With Out-of-Hospital Cardiac Arrest and Non–ST-Segment Elevation

Author

Spirito, Alessandro, primary, Vaisnora, Lukas, additional, Papadis, Athanasios, additional, Iacovelli, Fortunato, additional, Sardu, Celestino, additional, Selberg, Alexandra, additional, Bär, Sarah, additional, Kavaliauskaite, Raminta, additional, Temperli, Fabrice, additional, Pilgrim, Thomas, additional, Hunziker, Lukas, additional, Heg, Dik, additional, Windecker, Stephan, additional, and Raber, Lorenz, additional

Published
2022
Full Text
View/download PDF

12. Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients With Out-of-Hospital Cardiac Arrest

Author

Spirito, Alessandro, primary, Papadis, Athanasios, additional, Vaisnora, Lukas, additional, Iacovelli, Fortunato, additional, Sardu, Celestino, additional, Kavaliauskaite, Raminta, additional, Lanz, Jonas, additional, Temperli, Fabrice, additional, Asatryan, Babken, additional, Heg, Dik, additional, Hunziker, Lukas, additional, Windecker, Stephan, additional, Räber, Lorenz, additional, and Valgimigli, Marco, additional

Published
2022
Full Text
View/download PDF

13. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice

Author

Zanchin, Thomas, primary, Temperli, Fabrice, additional, Karagiannis, Alexios, additional, Zanchin, Christian, additional, Räsänen, Markus, additional, Koskinas, Konstantinos C., additional, Stortecky, Stefan, additional, Hunziker, Lukas, additional, Praz, Fabien, additional, Blöchlinger, Stefan, additional, Moro, Christina, additional, Moschovitis, Aris, additional, Seiler, Christian, additional, Billinger, Michael, additional, Heg, Dik, additional, Pilgrim, Thomas, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, and Räber, Lorenz, additional

Published
2018
Full Text
View/download PDF

14. Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction

Author

Koskinas, Konstantinos C., primary, Zanchin, Thomas, additional, Klingenberg, Roland, additional, Gencer, Baris, additional, Temperli, Fabrice, additional, Baumbach, Andreas, additional, Roffi, Marco, additional, Moschovitis, Aris, additional, Muller, Oliver, additional, Tüller, David, additional, Stortecky, Stefan, additional, Mach, Francois, additional, Lüscher, Thomas F., additional, Matter, Christian M., additional, Pilgrim, Thomas, additional, Heg, Dik, additional, Windecker, Stephan, additional, and Räber, Lorenz, additional

Published
2018
Full Text
View/download PDF

15. Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction

Author

Koskinas, Konstantinos C, Zanchin, Thomas, Klingenberg, Roland, Gencer, Baris, Temperli, Fabrice, Baumbach, Andreas, Roffi, Marco, Moschovitis, Aris, Muller, Oliver, Tüller, David, Stortecky, Stefan, Mach, Francois, Lüscher, Thomas F, Matter, Christian M, Pilgrim, Thomas, Heg, Dik, Windecker, Stephan, Räber, Lorenz, Koskinas, Konstantinos C, Zanchin, Thomas, Klingenberg, Roland, Gencer, Baris, Temperli, Fabrice, Baumbach, Andreas, Roffi, Marco, Moschovitis, Aris, Muller, Oliver, Tüller, David, Stortecky, Stefan, Mach, Francois, Lüscher, Thomas F, Matter, Christian M, Pilgrim, Thomas, Heg, Dik, Windecker, Stephan, and Räber, Lorenz

Abstract

BACKGROUND Early withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST-segment elevation myocardial infarction (STEMI) given the increased risk of thrombotic complications. This study assessed the frequency, predictors, and clinical impact of early prasugrel cessation in patients with STEMI undergoing primary percutaneous coronary interventions. METHODS AND RESULTS We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry [NCT02241291] and SPUM-ACS (Inflammation and Acute Coronary Syndromes) [NCT01000701]) and 1 STEMI trial (COMFORTABLE-AMI (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction) [NCT00962416]). Prasugrel treatment status at 1 year was categorized as no cessation; crossover to another P2Y-inhibitor; physician-recommended discontinuation; and disruption because of bleeding, side effects, or patient noncompliance. In time-dependent analyses, we assessed the impact of prasugrel cessation on the primary end point, a composite of cardiac death, myocardial infarction, and stroke. Of all 1830 included patients (17% women, mean age 59 years), 83% were treated with new-generation drug-eluting stents. At 1 year, any prasugrel cessation had occurred in 13.8% of patients including crossover (7.2%), discontinuation (3.7%), and disruption (2.9%). Independent predictors of any prasugrel cessation included female sex, age, and history of cerebrovascular event. The primary end point occurred in 5.2% of patients and was more frequent following disruption (hazard ratio 3.04, 95% confidence interval,1.34-6.91; =0.008), without significant impact of crossover or discontinuation. Consistent findings were observed for all-cause death, myocardial infarction, and stent thrombosis following prasugrel disruption. CONCLUSIONS In this contemporary study of patients with ST

Published
2018

16. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Non-coding RNAs in AMI Patients: A Substudy of the PACMAN-AMI Trial

Author

Ueki, Yasushi, Häner, Jonas, Losdat, Sylvain, Gargiulo, Giuseppe, Shibutani, Hiroki, Bär, Sarah, Otsuka, Tatsuhiko, Kavaliauskaite, Raminta, Mitter, Vera, Temperli, Fabrice, Spirk, David, Stortecky, Stefan, Siontis, George, Valgimigli, Marco, Windecker, Stephan, Gutmann, Clemens, Koskinas, Konstantinos C., Mayr, Manuel, and Raber, Lorenz

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results